First-line durvalumab (AstraZeneca) or durvalumab plus tremelimumab failed to extend overall survival in unselected patients with metastatic non-small cell lung cell (NSCLC) according to results from the MYSTIC trial recently presented at the European Society of Medical Oncology (ESMO) Immuno-Oncology 2018 Congress, in Geneva Switzerland. The We include a summary of the results in Annals of Oncology.
Durvalumab is a human IgG1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and CD80 molecules, and tremelimumab is a human IgG2 monoclonal antibody that blocks the activity of CTLA-4. Previous study reveal that the drugs were efficacious in treating NSCLC. Investigators have observed successful studies with immune checkpoint inhibitors and chemotherapy for frontline therapy for metastatic NSCLC. However, the use of two immunotherapy drugs without chemotherapy as first-line treatment requires further investigation according to the investigators. See the link below to review the results.